Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FCA 2019: Key Issues Include DOJ Dismissal, Statute Of Limitations

Executive Summary

Court rulings related to the False Claims Act (FCA) this year focused on whistleblower rules and further clarifying the theory of liability, given in the Supreme Court’s 2016 Escobar decision, Gibson Dunn health-care attorneys say.

You may also be interested in...



Avalign And Subsidiary Instrumed To Pay $9.5M In Uncleared Device Settlement

Avalign Technologies is paying $9.5m to settle fraud charges. The company and its Instrumed International subsidiary sold unapproved devices that they falsely claimed held pre-amendment status.

US High Court Won’t Hear FCA, Patent Cases

The US Supreme Court announced Monday that it won’t hear a much-watched case that could have limited the government’s ability to bring False Claims Act cases if it knew of the alleged misconduct. Two drug-world patent cases were also declined.

President Signs Opioids Bill Calling For Alternative Tech, More Pain-Control Research

Industry groups praised newly enacted opioid-control legislation Oct. 24. The legislation will put more attention on existing medtech alternatives to addictive opioids and support research on new devices. Industry was positive about the new law, despite its expansion of sunshine reporting requirements that they oppose.

Topics

UsernamePublicRestriction

Register

MT125933

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel